HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 2 (2005), Issue 8 (August)

1. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study.
   Lancet, 366(9483): 378-84. [Abstract] [Full-text]
2. Effects of CAPE-like compounds on HIV replication in vitro and modulation of cytokines in vivo.
   J Antimicrob Chemother, 56(2): 372-9. [Abstract] [Full-text]
3. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.
   J Antimicrob Chemother, 56(2): 380-7. [Abstract] [Full-text]
4. Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection.
   J Antimicrob Chemother, 56(2): 273-6. [Abstract] [Full-text]
5. Cyclotriazadisulfonamides: promising new CD4-targeted anti-HIV drugs.
   J Antimicrob Chemother, 56(2): 270-2. [Abstract] [Full-text]
6. Diversity of thymidine analogue resistance genotypes among newly diagnosed HIV-1-infected persons.
   J Antimicrob Chemother, 56(2): 265-9. [Abstract] [Full-text]
7. Transcription factor binding sites in the pol gene intragenic regulatory region of HIV-1 are important for virus infectivity.
   Nucleic Acids Res, 33(13): 4285-310. [Abstract] [Full-text]
8. Diagnoses of HIV-1 and HIV-2 in England, Wales, and Northern Ireland associated with west Africa.
   Sex Transm Infect, 81(4): 338-41. [Abstract] [Full-text]
9. Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients.
   J Clin Invest, 115(8): 2139-48. [Abstract] [Full-text]
10. HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation.
    J Clin Invest, 115(8): 2149-58. [Abstract] [Full-text]
11. Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier.
    Pharm Res, 22(8): 1259-68. [Abstract] [Full-text]
12. Anti-HIV-1 activity of anti-TAR polyamide nucleic acid conjugated with various membrane transducing peptides.
    Nucleic Acids Res, 33(13): 4345-56. [Abstract] [Full-text]
13. Unfolding of DNA quadruplexes induced by HIV-1 nucleocapsid protein.
    Nucleic Acids Res, 33(14): 4395-403. [Abstract] [Full-text]
14. Recombinant AAV2 transduction of primitive human hematopoietic stem cells capable of serial engraftment in immune-deficient mice.
    Proc Natl Acad Sci U S A, 102(31): 11053-8. [Abstract] [Full-text]
15. HIV-1 Nef down-regulates the hemochromatosis protein HFE, manipulating cellular iron homeostasis.
    Proc Natl Acad Sci U S A, 102(31): 11017-22. [Abstract] [Full-text]
16. A peptide inhibitor of HIV-1 assembly in vitro.
    Nat Struct Mol Biol, 12(8): 671-7. [Abstract] [Full-text]
17. The HIV-1 capsid protein C-terminal domain in complex with a virus assembly inhibitor.
    Nat Struct Mol Biol, 12(8): 678-82. [Abstract] [Full-text]
18. Multicenter performance evaluation of a transcription-mediated amplification assay for screening of human immunodeficiency virus-1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations.
    Transfusion, 45(8): 1258-66. [Abstract] [Full-text]
19. Pulmonary Mycobacterium sherrisii infection in a human immunodeficiency virus type 1-infected patient.
    J Clin Microbiol, 43(8): 4283-5. [Abstract] [Full-text]
20. Molecular detection of Cellulosimicrobium cellulans as the etiological agent of a chronic tongue ulcer in a human immunodeficiency virus-positive patient.
    J Clin Microbiol, 43(8): 4269-71. [Abstract] [Full-text]
21. Stability of human immunodeficiency virus type 1 proviral DNA in whole-blood samples.
    J Clin Microbiol, 43(8): 4249-50. [Abstract] [Full-text]
22. Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay.
    J Clin Microbiol, 43(8): 4234-6. [Abstract] [Full-text]
23. High seroprevalence of herpes simplex virus type 2 infection in French human immunodeficiency virus type 1-infected outpatients.
    J Clin Microbiol, 43(8): 4215-7. [Abstract] [Full-text]
24. Affordable, abbreviated roche monitor assay for quantification of human immunodeficiency virus type 1 RNA in plasma.
    J Clin Microbiol, 43(8): 4200-2. [Abstract] [Full-text]
25. Performance of a rapid immunochromatographic screening test for detection of antibodies to human immunodeficiency virus type 1 (HIV-1) and HIV-2: experience at a tertiary care hospital in South India.
    J Clin Microbiol, 43(8): 4194-6. [Abstract] [Full-text]
26. Comparison between sequence analysis and a line probe assay for testing genotypic resistance of human immunodeficiency virus type 1 to antiretroviral drugs.
    J Clin Microbiol, 43(8): 4186-8. [Abstract] [Full-text]
27. Model for assessment of proficiency of human immunodeficiency virus type 1 sequencing-based genotypic antiretroviral assays.
    J Clin Microbiol, 43(8): 3963-70. [Abstract] [Full-text]
28. Detection and quantification of human immunodeficiency virus type 1 p24 antigen in dried whole blood and plasma on filter paper stored under various conditions.
    J Clin Microbiol, 43(8): 3901-5. [Abstract] [Full-text]
29. Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT.
    J Clin Microbiol, 43(8): 3860-8. [Abstract] [Full-text]
30. Evaluation of the VACUTAINER PPT Plasma Preparation Tube for use with the Bayer VERSANT assay for quantification of human immunodeficiency virus type 1 RNA.
    J Clin Microbiol, 43(8): 3769-71. [Abstract] [Full-text]
31. Autoimmunity, alloimmunization and immunotherapy of AIDS.
    Autoimmun Rev, 4(6): 403-9. [Abstract] [Full-text]
32. Use of alternate coreceptors on primary cells by two HIV-1 isolates.
    Virology, 339(1): 136-44. [Abstract] [Full-text]
33. Natural controlled HIV infection: preserved HIV-specific immunity despite undetectable replication competent virus.
    Virology, 339(1): 70-80. [Abstract] [Full-text]
34. Scrambling of the amino acids within the transmembrane domain of Vpu results in a simian-human immunodeficiency virus (SHIVTM) that is less pathogenic for pig-tailed macaques.
    Virology, 339(1): 56-69. [Abstract] [Full-text]
35. Human immunodeficiency virus type 1 KK26-27 matrix mutants display impaired infectivity, circularization and integration but not nuclear import.
    Virology, 339(1): 21-30. [Abstract] [Full-text]
36. Mood disorders in the medically ill: scientific review and recommendations.
    Biol Psychiatry, 58(3): 175-89. [Abstract] [Full-text]
37. The gastrointestinal tract is critical to the pathogenesis of acute HIV-1 infection.
    J Allergy Clin Immunol, 116(2): 419-22. [Abstract] [Full-text]
38. The 3'-azido group is not the primary determinant of 3'-azido-3'-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1.
    J Biol Chem, 280(32): 29047-52. [Abstract] [Full-text]
39. Processing of viral DNA ends channels the HIV-1 integration reaction to concerted integration.
    J Biol Chem, 280(32): 29334-9. [Abstract] [Full-text]
40. Antigenic properties of peptide mimotopes of HIV-1-associated carbohydrate antigens.
    J Biol Chem, 280(32): 28959-65. [Abstract] [Full-text]
41. Prevalence of clinical isolates of Cryptococcus gattii serotype C among patients with AIDS in Sub-Saharan Africa.
    J Infect Dis, 192(5): 888-92. [Abstract] [Full-text]
42. Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef.
    J Infect Dis, 192(5): 749-59. [Abstract] [Full-text]
43. Low CD4 T cell counts before HIV-1 seroconversion do not affect disease progression in Ethiopian factory workers.
    J Infect Dis, 192(5): 739-48. [Abstract] [Full-text]
44. Elevated T cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers.
    J Infect Dis, 192(5): 728-38. [Abstract] [Full-text]
45. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment.
    J Infect Dis, 192(5): 720-7. [Abstract] [Full-text]
46. Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk.
    J Infect Dis, 192(5): 713-9. [Abstract] [Full-text]
47. STD/HIV association: effects on semen characteristics.
    Arch Androl, 51(5): 361-5. [Abstract] [Full-text]
48. Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA).
    Antiviral Res, 67(2): 83-92. [Abstract] [Full-text]
49. HIV genetic diversity: any implications for drug resistance?
    Infection, 33(4): 299-301. [Abstract] [Full-text]
50. Cost of AIDS care in Mexico: what are its main individual predictors?
    Arch Med Res, 36(5): 560-6. [Abstract] [Full-text]
51. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study.
    Lancet, 366(9485): 549-55. [Abstract] [Full-text]
52. Interleukin-10 promoter gene polymorphisms have no clear influence on interleukin-10 protein secretion in AIDS-associated B-cell lines.
    Biochem Biophys Res Commun, 335(2): 529-35. [Abstract] [Full-text]
53. CCR5 N-terminal region plays a critical role in HIV-1 inhibition by Toxoplasma gondii-derived cyclophilin-18.
    J Biol Chem, 280(33): 29570-7. [Abstract] [Full-text]
54. Human immunodeficiency virus mutations during the first month of infection are preferentially found in known cytotoxic T-lymphocyte epitopes.
    J Virol, 79(17): 11523-8. [Abstract] [Full-text]
55. Human immunodeficiency virus Nef induces rapid internalization of the T-cell coreceptor CD8alphabeta.
    J Virol, 79(17): 11422-33. [Abstract] [Full-text]
56. Human immunodeficiency virus type 1 Vpr-dependent cell cycle arrest through a mitogen-activated protein kinase signal transduction pathway.
    J Virol, 79(17): 11366-81. [Abstract] [Full-text]
57. Phylodynamic analysis of human immunodeficiency virus type 1 in distinct brain compartments provides a model for the neuropathogenesis of AIDS.
    J Virol, 79(17): 11343-52. [Abstract] [Full-text]
58. Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation.
    J Virol, 79(17): 11247-58. [Abstract] [Full-text]
59. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope.
    J Virol, 79(17): 11214-24. [Abstract] [Full-text]
60. Endothelial cells promote human immunodeficiency virus replication in nondividing memory T cells via Nef-, Vpr-, and T-cell receptor-dependent activation of NFAT.
    J Virol, 79(17): 11194-204. [Abstract] [Full-text]
61. The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells.
    J Virol, 79(17): 11179-86. [Abstract] [Full-text]
62. Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion.
    J Virol, 79(17): 11161-9. [Abstract] [Full-text]
63. Differential pathogenesis of primary CCR5-using human immunodeficiency virus type 1 isolates in ex vivo human lymphoid tissue.
    J Virol, 79(17): 11151-60. [Abstract] [Full-text]
64. Ubiquitylation of Cdk9 by Skp2 facilitates optimal Tat transactivation.
    J Virol, 79(17): 11135-41. [Abstract] [Full-text]
65. Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases.
    J Virol, 79(17): 10978-87. [Abstract] [Full-text]
66. HIV-1 Gag-RNA interaction occurs at a perinuclear/centrosomal site; analysis by confocal microscopy and FRET.
    Traffic, 6(9): 741-55. [Abstract] [Full-text]
67. Recruitment and retention in a longitudinal palliative care study.
    Appl Nurs Res, 18(3): 167-77. [Abstract] [Full-text]
68. The problems of indeterminate HIV results in blood transfusion services in Nigeria.
    Trop Doct, 35(3): 166-7. [Abstract] [Full-text]
69. L565M mutation in HIV-1 glycoprotein 41 stabilizes the coiled-coil structure.
    Biochem Biophys Res Commun, 335(1): 112-6. [Abstract] [Full-text]
70. NF-kappaB-repressing factor inhibits elongation of human immunodeficiency virus type 1 transcription by DRB sensitivity-inducing factor.
    Mol Cell Biol, 25(17): 7473-83. [Abstract] [Full-text]
71. Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.
    J Med Chem, 48(17): 5580-8. [Abstract] [Full-text]
72. Learning multiple evolutionary pathways from cross-sectional data.
    J Comput Biol, 12(6): 584-98. [Abstract] [Full-text]
73. Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count.
    Am J Epidemiol, 162(5): 471-8. [Abstract] [Full-text]
74. Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library.
    J Biol Chem, 280(34): 30083-90. [Abstract] [Full-text]
75. Hypersensitivity of HIV-1-infected cells to reactive sulfonamide metabolites correlated to expression of the HIV-1 viral protein tat.
    J Pharmacol Exp Ther, 314(3): 1218-25. [Abstract] [Full-text]
76. In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine.
    J Pharmacol Exp Ther, 314(3): 1202-9. [Abstract] [Full-text]
77. Early proliferation of CCR5(+) CD38(+++) antigen-specific CD4(+) Th1 effector cells during primary HIV-1 infection.
    Blood, 106(5): 1660-7. [Abstract] [Full-text]
78. Signaling mechanisms of HIV-1 Tat-induced alterations of claudin-5 expression in brain endothelial cells.
    J Cereb Blood Flow Metab, 25(9): 1159-70. [Abstract] [Full-text]
79. HIV/AIDS: sex, abstinence, and behaviour change.
    Lancet Infect Dis, 5(9): 590-3. [Abstract] [Full-text]
80. GBV-C/HGV and HIV-1 coinfection.
    Braz J Infect Dis, 9(2): 122-5. [Abstract] [Full-text]
81. Factors associated with wanting to know HIV results in South Africa.
    AIDS Patient Care STDS, 19(8): 518-25. [Abstract] [Full-text]
82. HIV disclosure by men who have sex with men to immediate family over time.
    AIDS Patient Care STDS, 19(8): 506-17. [Abstract] [Full-text]
83. Syphilis, chlamydia, and gonorrhea screening in HIV-infected patients in primary care, San Francisco, California, 2003.
    AIDS Patient Care STDS, 19(8): 495-8. [Abstract] [Full-text]
84. Evidence that the species barrier of human immunodeficiency virus-1 does not extend to uptake by the blood--brain barrier: comparison of mouse and human brain microvessels.
    Life Sci, 77(19): 2361-8. [Abstract] [Full-text]
85. The synthetic peptide derived from the NH2-terminal extracellular region of an orphan G protein-coupled receptor, GPR1, preferentially inhibits infection of X4 HIV-1.
    J Biol Chem, 280(35): 30924-34. [Abstract] [Full-text]
86. Heterosexual transmission of novel CRF01_AE and subtype B recombinant forms of HIV type 1 in northern Thailand.
    AIDS Res Hum Retroviruses, 21(8): 734-8. [Abstract] [Full-text]
87. Evidence for host-driven selection of the HIV type 1 vpr gene in vivo during HIV disease progression in a transfusion-acquired cohort.
    AIDS Res Hum Retroviruses, 21(8): 728-33. [Abstract] [Full-text]
88. In HIV type 1-infected children cytotoxic T lymphocyte responses are associated with greater reduction of viremia under antiretroviral therapy.
    AIDS Res Hum Retroviruses, 21(8): 719-27. [Abstract] [Full-text]
89. HIV type 1 cervicovaginal reservoirs in the era of HAART.
    AIDS Res Hum Retroviruses, 21(8): 714-8. [Abstract] [Full-text]
90. Comparison of HIV type 1 protease inhibitor susceptibility results in viral samples analyzed by phenotypic drug resistance assays and by six resistance algorithms: an analysis of a subpopulation of the CHORUS cohort.
    AIDS Res Hum Retroviruses, 21(8): 696-701. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.